EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial

Donel S iD, Dhini Aiyulie Novri, Yulis Hamidy iD, Maya Savira iD

F1000Research · 2023

DOI: 10.12688/f1000research.125944.2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift F1000Research, 2023. Verfasst von Donel S und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia. Hauptthemen laut MEDLINE: Labetalol, Pre-Eclampsia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preeclampsia is a highly prevalent disease among pregnant women. In the event of hypertensive emergency, nifedipine, labetalol, and hydralazine are assigned as first-line therapies in preeclampsia. Further studies are needed to compare the effectiveness of these drugs to find the most cost-effective drug with minimal side effects. This study aimed to compare the effectiveness of these drugs in lowering blood pressure during hypertensive emergencies in severe preeclampsia.

Methods

60 pregnant women with severe preeclampsia were recruited in this multiple centre double-blind randomized clinical trial from May 2021 to April 2022 in Indonesia. The patients were divided equally into three groups and treated with three doses of nifedipine, labetalol, and hydralazine, respectively within one hour with 20 minutes interval. The effectiveness was measured based on systolic and diastolic blood pressures, and mean arterial pressure (MAP). The observation was carried out until five hours post-third dose administration.

Results

The blood pressure was reduced significantly after the administration of the first to the third dose of each antihypertensive (plabetalol>hydralazine (57.49%, 42.13%, and 40.87%, respectively) for single dose and hydralazine>nifedipine>labetalol (111.3%, 85.12%, and 90.04%, respectively) for triple dose.

Conclusions

Nifedipine is the most effective drug to reduce the blood pressure when single dose administration is used, but requires more doses to further reduce the blood pressure. Hydralazine is the most effective when the drug administration is maxed up to three doses within 60 minutes with 20 minutes interval. Thai Clinical Trials Registry (TCTR): TCTR20221014007 (14/10/2022)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LabetalolPre-EclampsiaFemaleHumansPregnancyNifedipineAntihypertensive AgentsHydralazine

Stichwörter der Autor:innen

Hypertension; gestation; systolic blood pressure; diastolic blood pressures; me…

Substanzen

LabetalolNifedipineAntihypertensive AgentsHydralazine

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia.
  • Department of Pharmacology, Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia.
  • Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia.

ORCID-Profile: Donel S, Yulis Hamidy, Maya Savira

Zitieren

APA

S, D., Novri, D. A., Hamidy, Y., & Savira, M. (2023). Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial. F1000Research. https://doi.org/10.12688/f1000research.125944.2

Vancouver

S D, Novri DA, Hamidy Y, Savira M. Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial. F1000Research. 2023. doi:10.12688/f1000research.125944.2

BibTeX
@article{S2023,
  author = {S, Donel and Novri, Dhini Aiyulie and Hamidy, Yulis and Savira, Maya},
  title = {Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial},
  journal = {F1000Research},
  year = {2023},
  doi = {10.12688/f1000research.125944.2}
}
Kostenlos starten →